Bausch + Lomb (US:BLCO)2026-02-18 14:02Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue of $5.101 billion, up 5% [13][22] - Adjusted EBITDA for Q4 was $330 million, a 27% increase year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [12][20] - The full-year adjusted EBITDA was $891 million, reflecting a strong operating leverage and financial discipline [20][23] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [15] - Surgical segment revenue in Q4 was $249 million, a 3% increase, with full-year revenue of $894 million, up 4% [17] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [18] Market Data and Key Metrics Changes - The U.S. branded RX business in the pharma segment grew by 21% in Q4 and 13% for the full year, driven by strong performance from MIEBO [18] - Contact lens revenue grew by 8% in Q4 and 7% for the full year, with daily SiHy lenses showing significant growth [16] - The international market for contact lenses grew by 6% in Q4, with China seeing a 7% increase [16] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline to drive sustained growth [5][6] - There is a strong commitment to expanding the dry eye portfolio, with MIEBO expected to exceed peak sales of $600 million due to its successful market penetration [26][27] - The company aims to leverage its diversified product offerings to maintain a competitive advantage in the eye health market [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow faster than the market in 2026, with expectations for revenue growth across all segments [22][23] - The company highlighted the importance of execution and operational improvements as key drivers of future success [36][38] - Management acknowledged the competitive landscape but remains optimistic about the company's positioning and product quality [53][56] Other Important Information - The company expects adjusted EBITDA growth of approximately 15% year-over-year for 2026, with a focus on margin expansion [23][24] - The adjusted tax rate for the full year 2025 was 10%, lower than previous guidance, primarily due to one-time adjustments [21] Q&A Session Summary Question: What are the key areas to execute for growth in 2026? - Management emphasized the importance of execution and structural improvements in the P&L, highlighting the successful implementation of Vision 2027 [36][38] Question: What lessons can be learned from MIEBO's success? - Management noted that strong execution and a positive benefit-risk profile contributed to MIEBO's success, which will inform future pipeline strategies [40][41] Question: How will MIEBO's growth trajectory be impacted by steady investments? - Management expects continued strong growth for MIEBO, with a focus on targeted investments as the product transitions from launch to growth phase [48][51] Question: What are the competitive dynamics in the market? - Management acknowledged competition but expressed confidence in their strong market position, particularly in the pharma segment with leading products [53][56]